News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: National Institute for Clinical Excellence (NICE) Issues Final Appraisal Determination (FAD) with Unrestricted Recommendation for Pradaxa® (dabigatran etexilate) for Patients with Non-Valvular Atrial Fibrillation1


11/2/2011 7:44:47 AM

INGELHEIM, Germany--(BUSINESS WIRE)--For NON-US, UK & Canada Media Only

The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has issued a Final Appraisal Determination (FAD)1 recommending the novel oral anticoagulant, Pradaxa® (dabigatran etexilate), as a treatment option without any restrictions within its licensed indication for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation (AF) with one or more risk factors.* The FAD will form the guidance to the National Health Service (NHS) in England and Wales, which is expected to be published in December.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES